Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.

BACKGROUND Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system. Thus, we hypothesized that the best concomitant antithrombotic therapy (recombinant [r]-hirudin, heparin, or aspirin) will maximally accelerate thrombolysis by r-tissue-type plasminogen activator (rTPA) and reduce residual thrombus. METHODS AND RESULTS Occlusive thrombi were formed in the carotid arteries of 29 pigs (by balloon dilatation followed by endarterectomy at the site of injury-induced vasospasm) and matured for 30 minutes before rTPA was started, with or without antithrombotic therapy. Thrombolysis was assessed with the use of angiography and measurement of residual thrombus. Pigs were allocated to one of five treatments: placebo, rTPA, rTPA plus r-hirudin, rTPA plus heparin, or rTPA plus intravenous aspirin. No placebo-treated pig reperfused. Two of six animals treated with rTPA alone reperfused compared with seven of seven animals treated with rTPA plus r-hirudin (reperfusion time, 33 +/- 10 minutes), six of seven animals treated with rTPA plus heparin (reperfusion time, 110 +/- 31 minutes), and two of six animals with rTPA plus aspirin. The activated partial thromboplastin time was prolonged in only the rTPA plus r-hirudin group (25 +/- 0.1 times baseline) and the rTPA plus heparin group (5.3 +/- 0.2 times baseline). Residual 111In-platelet and 125I-fibrin(ogen) depositions were lower in the heparin-treated group and lowest in the r-hirudin-treated group (heparin versus hirudin, respectively; incidence of residual macroscopic thrombus was six of six animals versus two of seven [P = .01]; 125I-fibrin(ogen), 170 +/- 76 versus 48 +/- 6 x 10(6) molecules/cm2 [P = .02]; 111In-platelets, 47 +/- 15 versus 13 +/- 2 x 10(6)/cm2, P = .10). No pigs developed spontaneous bleeding. CONCLUSIONS Thrombin inhibition with heparin or r-hirudin significantly accelerated thrombolysis of occlusive platelet-rich thrombosis, but only the best antithrombotic therapy (r-hirudin) eliminated or nearly eliminated residual thrombus.

[1]  V. Fuster,et al.  Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. , 1994, Circulation.

[2]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[3]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[4]  V. Fuster,et al.  Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. , 1994, Journal of the American College of Cardiology.

[5]  C. Cannon,et al.  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.

[6]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[7]  W. Owen,et al.  Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[9]  H. Anderson,et al.  Combination of Inhibition of Thrombin and Blockade of Thromboxane A2 Synthetase and Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries , 1992, Circulation.

[10]  M. Simoons,et al.  Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). , 1992, Journal of the American College of Cardiology.

[11]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[12]  S. Roux,et al.  Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. , 1992, Journal of the American College of Cardiology.

[13]  V. Fuster,et al.  Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[14]  J. Miletich,et al.  Relative Importance of Thrombin Compared With Plasmin‐Mediated Platelet Activation in Response to Plasminogen Activation With Streptokinase , 1991, Circulation.

[15]  V. Fuster,et al.  Dynamic thrombosis and thrombolysis. Role of antithrombins. , 1991, Circulation.

[16]  E. Braunwald,et al.  Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. , 1991, Journal of the American College of Cardiology.

[17]  Burton E. Sobel,et al.  Relative Efficacy of Antithrombin Compared With Antiplatelet Agents in Accelerating Coronary Thrombolysis and Preventing Early Reocclusion , 1991, Circulation.

[18]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[19]  W J Penny,et al.  Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. , 1990, Circulation.

[20]  M J Davies,et al.  A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.

[21]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[22]  J. Chesebro,et al.  Platelet aggregation and interaction with the coagulation system: implications for antithrombotic therapy in arterial thrombosis , 1990 .

[23]  M. Rånby.  On the properties of the international standards for tissue plasminogen activator. , 1990, Thrombosis and haemostasis.

[24]  P. Hogg,et al.  Heparin promotes the binding of thrombin to fibrin polymer. Quantitative characterization of a thrombin-fibrin polymer-heparin ternary complex. , 1990, The Journal of biological chemistry.

[25]  P. Hogg,et al.  Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates. , 1990, The Journal of biological chemistry.

[26]  F. Markwardt,et al.  Antithrombin effects of native and recombinant hirudins. , 1990, Biomedica biochimica acta.

[27]  H. Gold,et al.  Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. , 1990, Circulation.

[28]  J. Soria,et al.  Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. , 1989, Blood.

[29]  G. FitzGerald,et al.  Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. , 1989, Circulation research.

[30]  F. Markwardt,et al.  Studies on antithrombotic effects of recombinant hirudin. , 1989, Thrombosis research.

[31]  P. Hogg,et al.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  F. Bochner,et al.  Measurement of Aspirin Concentrations in Portal and Systemic Blood in Pigs: Effect on Platelet Aggregation, Thromboxane and Prostacyclin Production , 1989, Thrombosis and Haemostasis.

[33]  W J Penny,et al.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. , 1989, Circulation.

[34]  H. Ferres,et al.  An investigation of methods to prevent fibrinogen degradation during processing of plasma samples containing the fibrinolytic agents, APSAC and t-PA , 1989 .

[35]  J. Hirsh,et al.  Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. , 1989, The Biochemical journal.

[36]  K. Mann,et al.  Activation/inactivation of human factor V by plasmin. , 1989, Blood.

[37]  B. Schmidt,et al.  Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. , 1988, Thrombosis research.

[38]  V. Fuster,et al.  Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. , 1988, Circulation.

[39]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[40]  Sol Sherry,et al.  Thrombolytic Therapy: Current Status , 1988 .

[41]  S. Hanson,et al.  Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Topol,et al.  Monitoring of Hemostasis Parameters During Coronary Thrombolysis with Recombinant Tissue-Type Plasminogen Activator , 1988, Thrombosis and Haemostasis.

[43]  T. Aoyama,et al.  Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin. , 1988, Japanese circulation journal.

[44]  E. Topol,et al.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.

[45]  M. Dewanjee.  Methods of Assessment of Thrombosis in Vivo , 1987, Annals of the New York Academy of Sciences.

[46]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[47]  J. Loscalzo,et al.  Tissue plasminogen activator promotes platelet disaggregation in plasma. , 1987, The Journal of clinical investigation.

[48]  V. Fuster,et al.  Electrical Aggregometry in Whole Blood from Human, Pig and Rabbit , 1986, Thrombosis and Haemostasis.

[49]  H. Hod,et al.  Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. , 1986, Circulation.

[50]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[51]  A. Jaffe,et al.  Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. , 1986, Journal of the American College of Cardiology.

[52]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[53]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.

[54]  P. Gaffney,et al.  A Collaborative Study of a Proposed International Standard for Tissue Plasminogen Activator (t-PA) , 1985, Thrombosis and Haemostasis.

[55]  J. Jespersen,et al.  A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision. , 1983, Haemostasis.

[56]  E. Shaw,et al.  In vivo studies of a synthetic inhibitor of thrombin. , 1982, The Journal of laboratory and clinical medicine.

[57]  T. Peters,et al.  A candidate reference method for determination of total protein in serum. I. Development and validation. , 1981, Clinical chemistry.

[58]  J. Holbrook,et al.  The multiple complexes formed by the interaction of platelet factor 4 with heparin. , 1980, The Biochemical journal.

[59]  C. Kluft.  Studies on the Fibrinolytic System in Human Plasma: Quantitative Determination of Plasminogen Activators and Proactivators , 1979, Thrombosis and Haemostasis.

[60]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[61]  M. Friedman,et al.  The pathogenesis of a coronary thrombus. , 1966, The American journal of pathology.

[62]  A. Bloom.  The Release of Thrombin from Fibrin by Fibrinolysin , 1962, British journal of haematology.

[63]  S. Niewiarowski,et al.  Comparative Studies of the Fibrinolytic System of Sera of Various Vertebrates , 1959, Thrombosis and Haemostasis.

[64]  M. Pitkänen,et al.  Noradrenaline and adrenaline in the urine part I. their chemical determination , 1955 .

[65]  A. Gornall,et al.  Determination of serum proteins by means of the biuret reaction. , 1949, The Journal of biological chemistry.

[66]  W. Seegers,et al.  NOTE ON THE ADSORPTION OF THROMBIN ON FIBRIN. , 1945, Science.